However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects
RiskBenefit Assessment and Pharmacovigilance Needs Given the widespread use of GLP-1RAs and other incretin-based agents for obesity and T2D, comprehensive evaluation of even common GI adverse effects remains limited
With rapid weight loss, that support structure can change faster than the skin can respond
Compounded GLP-1s have not been evaluated by the FDA, but side effects are expected to be similar to other GLP-1-based medications reviewed by the FDA, which have the following side effects: nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar), flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)